PharmaDepth

Company profile

VANDA PHARMACEUTICALS INC.

NASDAQ:VNDABiotechnology: Pharmaceutical Preparations

Drug pipeline (7)

AssetStageRevenueTrialsStatus
FANAPTapproved$36.0MQ2 202612approved
PONVORYapproved$7.9MQ2 202615approved
HETLIOZapproved$5.6MQ2 202625approved
NEREUSapproved$1.0MQ2 202619approved
BYSANTIapproved—4approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (76)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03291041phase2completed2016-07-012017-11-01Vanda PharmaceuticalsA Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
NCT01402076phase1completed2011-08-012011-08-01Vanda PharmaceuticalsA Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects
NCT04712734phase1completed2021-01-132022-08-30Vanda PharmaceuticalsA Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
NCT05344365phase2withdrawn2022-06-012023-11-01Vanda PharmaceuticalsA Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
NCT07446439phase3recruiting2026-03-272026-12-01Vanda PharmaceuticalsA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

FDA applications (6)

ApplicationApprovedTypeApplicantProducts
NDA 2203582026-02-20NDAVANDA PHARMACEUTICALS INC
NDA 2201522025-12-30NDAVANDA PHARMACEUTICALS INC
NDA 2134982021-03-18NDAVANDA PHARMACEUTICALS INC
NDA 2145172020-12-01NDAVANDA PHARMACEUTICALS INC
NDA 2056772014-01-31NDAVANDA PHARMACEUTICALS INC